Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: SHAILY

Shaily Engineering Plastics

Results filed 29 October 2026 · Market cap ₹14,580 crore · PE 71.6

GrowthGuidance maintainedTranscript read

Revenue
+24.5%
on a year ago
EBITDA
+22.5%
on a year ago
Profit to shareholders
+19.6%
on a year ago
EBITDA margin
30.4%
+0.8 pts on last quarter

Shaily Engineering Plastics delivered its highest quarterly consolidated revenue of ₹319.5 crore (+24% YoY) and crossed ₹100 crore in quarterly EBITDA driven by 78% growth in its Healthcare segment. The company delivered 10.4 million pen injectors in Q2 FY27 and remains on track to surpass its full-year guidance of 36 million pens while actively commissioning an additional 25 million pen line. However, the Consumer segment contracted 14% YoY amidst weak US/European demand, and management declined to quantify one-off items embedded in the sharp QoQ increase in other expenses.

Shaily Engineering Plastics Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue320281+13.8%257+24.5%
Operating profit (EBIT)82.8569.01+20.1%67.32+23.1%
Operating margin25.9%24.6%+134 bps26.2%−30 bps
Other income4.720.25+1788.0%2.28+107.0%
Exceptional items00–0–
Profit before exceptional items and tax84.5665.94+28.2%65.7+28.7%
Profit to shareholders61.2748.01+27.6%51.25+19.6%
Earnings per share (₹)13.3210.45+27.5%11.15+19.5%

Source: Shaily Engineering Plastics Limited’s filing to NSE, 29 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Healthcare has become the primary growth driver, contributing 55% of revenue with 78% YoY growth in Q2 FY27.
    SourceTranscript original page 3, Amit Sanghvi: 'Healthcare is now the primary engine of our business, contributing 55% of revenue and growing 78% year-on-year... Revenue stood at INR175 crores in Q2, up 78% year-on-year.'
  • EBITDA crossed ₹100 crore milestone in a single quarter for the first time, reaching ₹101.8 crore with a 31.9% margin.
    SourceTranscript original page 3, Amit Sanghvi: 'EBITDA rose 25% year-over-year and 22% sequentially to INR102 crores at a margin of 31.9%. Importantly, this is the first time we have crossed the INR100 crores EBITDA milestone in a single quarter.'
  • Healthcare pen device volumes reached 10.4 million units in Q2 FY27, tracking to exceed the full-year guidance of 36 million units.
    SourceTranscript original page 4, Amit Sanghvi: 'We have delivered 10.4 million devices in the quarter and remain on track to exceed our full year guidance of 36 million devices.'

Guidance

MetricGuidancePeriod
Healthcare Device Volumes
SourceTranscript original page 4, Amit Sanghvi: 'remain on track to exceed our full year guidance of 36 million devices.'
Exceed full year guidance of 36 million devicesFY27
Consumer Segment Revenue Growth
SourceTranscript original page 11, Sanjay Shah: 'business will, on the consumer part of it, it will remain flat for the current year.'
Business expected to remain flat net-net for the current fiscal yearFY27
UK Subsidiary Profitability
SourceTranscript original pages 11-12, 15, Sanjay Shah & Amit Sanghvi: 'on an overall basis for the whole year, we would not have a loss... EBITDA positive as well as PAT positive for the full year.'
Expected to achieve full year EBITDA and PAT breakeven/profitability despite H1 lossFY27

Device volume target reiterated as exceeding 36 million units, though management declined to formally increase the numerical target pending machine qualifications.

Tailwinds

  • Surge in Healthcare pen injector volumes led by global generic GLP-1 momentum and expansion into Canada, Brazil, and India.
    SourceTranscript original pages 3-4, Amit Sanghvi: 'Healthcare revenue was INR318 crores, up 81%. Growth was led from our pen injector platforms, particularly the GLP-1 programs... generic competition is gaining momentum.'
  • Plant capacity utilization improved to 52.5% in Q2 FY27 from 47.8% a year ago, generating operational productivity.
    SourceTranscript original page 6, Sanjay Shah: 'Machine utilization across our plants rose to 52.5% in quarter 2 compared to 47.8% a year ago.'
  • Credit rating upgraded for short-term facilities to CARE A1+ from CARE A1, while long-term reaffirmed at CARE A+ stable.
    SourcePresentation original page 5 & Transcript original page 6, Sanjay Shah: 'upgraded our short-term facilities to CARE A1+ from CARE A1.'

Headwinds

  • Consumer segment revenue contracted 14% YoY in Q2 FY27 due to weak European and US demand for home furnishings.
    SourceTranscript original pages 3, 5, Amit Sanghvi: 'demand for home furnishings in Europe and the U.S. remained subdued... Consumer revenue was INR116 crores, down 14% year-on-year and flat sequentially.'
  • Consolidated other expenses rose 45% QoQ (to ₹59.9 crore from ₹43.0 crore inferred, and up 28.8% YoY from ₹46.5 crore), partly driven by one-off expenses and business mix changes.
    SourceTranscript original page 11, Sanjay Shah: 'there will be some one-off costs which would have been incurred... a change in the business mix for which there would be some higher expenses'; Presentation original page 11: Other Expenses at ₹59.9 Cr.
  • Pricing pressure and built-in contractual price erosion of 10% to 15% on drug delivery pens.
    SourceTranscript original page 14, Amit Sanghvi: 'There is pricing pressure. And for all the long-term contracts that we currently have in place, a) price erosion has already been built into that contract.'

New businesses and products

new product · Launched at CPHI, ~80% development completed; currently seeking pharmaceutical commercial partner

Toby Reusable auto-injector platform for GLP-1 therapies

Expected benefit
Conservatively 70% more sustainable than disposable auto-injectors, reduces cold chain logistics costs to 20-25%, targets innovator pharma globally
Risks
Remaining 20% development work still underway; requires partner sign-up and long regulatory onboarding cycle
Timeline
80% completed as of October 2026; looking for partner
SourceTranscript original pages 4, 7-9, Amit Sanghvi: 'launched our latest innovation, the Toby Reusable auto-injector... completed potentially 80% of development... cold chain costs are down to 20%, 25%'

capacity expansion · Under planning / implementation

Abu Dhabi medical device manufacturing facility

Expected benefit
Adds 75 million pens annually to support global GLP-1 opportunity
Risks
Execution risk in international geography; timeline extended to end of FY28
Timeline
Ready by end of FY28
Investment
AED 130-150 million (~₹350 crore)
SourcePresentation original page 5: 'Setting up of a Facility in Abu Dhabi for manufacturing Medical Devices... Expected investment of AED 130–150 million (~ Rs.350 Crores)... add a capacity of 75 Mn pens annually'; Transcript original page 11, Amit Sanghvi confirming end of FY28

capacity expansion · Machines received and installed; qualification starting next week

25 Million Pens capacity addition (Neo line)

Expected benefit
Increases pen manufacturing capacity to relieve internal ramp-up bottlenecks and take additional insulin volumes
Risks
Ramp-up timing dependent on successful qualification
Timeline
Commercial sales expected to start in December 2026
SourcePresentation original page 5: '25 Mn Pens capacity is expected to be added'; Transcript original page 11, Amit Sanghvi: 'It starts qualification next week. If all goes well, we should be in a position to start selling from that capacity in December.'

new business · Consumer Electronics commercial supplies commenced; Semiconductor Packaging trial production in Q3 FY27 with Korean technical partner

Consumer Electronics and Semiconductor Packaging (JEDEC trays, tapes, wafer boxes)

Expected benefit
Diversification into high-precision electronics components; higher margin than consumer/industrial base
Risks
Dependence on pace of OSAT/TSAT ramp-up in India; customer qualifications required
Timeline
Semiconductor Packaging commercial shipments starting Q4 FY27; scale-up opportunity over next 36 months
Investment
Indicative initial capex of around ₹100 crore
SourceTranscript original pages 5, 10, 15, Amit Sanghvi & Sanjay Shah: 'Commercial supplies have commenced for Consumer Electronics... start trial production of Semiconductor Packaging in Q3 FY27, expect to start commercial shipments in Q4.'

new product · Mira close to finalizing customer; Toby Emergency Use has 2 active customers in development

Mira on-body auto-injector and Toby Emergency Use auto-injector

Expected benefit
Expands therapeutic coverage into emergency use and oncology with higher per-device realizations and margins
Risks
Long development cycles and clinical validation
Timeline
Mira: 14-month timeline to deliver clinical batches post customer finalization; Toby Emergency Use: clinical batches due end of CY27, commercial production end of CY28
Investment
High upfront development and capex costs
SourceTranscript original pages 7, 14, Amit Sanghvi: 'we're close to finalizing a customer for the on-body Mira... Toby Emergency Use... clinical batches are due end of '27, which means that earliest commercialization to production will be probably end of calendar '28.'

Things to check

  • Unquantified surge in other expenses (up 45% QoQ) which management acknowledged included one-offs but declined to disclose the exact amount.
    SourceTranscript original page 11, Vinil Shah: 'Would you like to quantify the one-off expense, Sir?' Sanjay Shah: 'I don't think I'll be able to quantify that currently.'
  • Foreign subsidiary recorded consecutive quarterly losses (EBITDA loss of ~₹7 crore in H1 FY27) with unbilled/unrecognized revenue due to missing customer confirmations.
    SourceTranscript original pages 11-12, 15, Akhil Parekh & Sanjay Shah: 'our subsidiary is incurring losses for the last 3 quarters... making a loss for the last 2 quarters. There has been some revenue which we have not recognized in quarter 2... customer confirmations pending'

How the call went

Management demonstrated strong command of device technicalities, customer development pipelines, and supply-chain dynamics, while being guarded on upcoming year forecasts and specific non-recurring cost breakdowns.

Specific or vague
Management provided granular unit volumes (10.4 million devices in Q2), product pipeline milestones, and timeline targets for multiple platforms, but declined to quantify one-off expenses and specific FY28 volume projections.
Candour
Direct acknowledgement of consumer demand weakness in Western markets, pricing erosion built into pen contracts, and UK subsidiary losses in H1.
The hard questions
Directly addressed analyst inquiries regarding customer product recalls involving dosing errors (clarifying it was third-party labeling/packaging error, not device design), pricing pressure, and subsidiary losses.

What analysts pressed on

  • Whether Toby Reusable could cannibalize existing single-use auto-injector/pen volumes
  • Impact of regulatory product recalls on pen volumes
  • Exact magnitude and breakdown of 45% QoQ surge in other expenses
  • Underlying cause and persistence of losses in the UK subsidiary
  • Impact of 10-15% annual pen price erosion on operating margins

Answers that sidestepped

  • Refusal to quantify the one-off portion of the other expenses spike in Q2 FY27 ('I don't think I'll be able to quantify that currently')
  • Deflection on providing FY28 pen delivery volume guidance despite exceeding run-rates

Numbers against the story

Management emphasized that the business mix has shifted towards Healthcare (55% of consolidated revenue, up 78% YoY) and that gross margins rebounded 70 bps YoY to 60.0%. This narrative is confirmed by reported numbers: consolidated EBITDA grew 25% YoY to ₹101.8 crore, and standalone EBITDA margin reached 32.58% (+389 bps YoY). However, management characterized the Consumer business as 'steadying', while the reported numbers show a persistent YoY decline (-14% in Q2 and -19% in H1) due to continued softness in Western home furnishing markets.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.